Addendum
Substituted Malononitriles in Neoplastic Diseases in Man

N. L. Petrikis, H. R. Bierman, and M. B. Shimkin

(Laboratory of Experimental Oncology, National Cancer Institute, National Institutes of Health, Public Health Service, Federal Security Agency and the Division of Medicine, University of California School of Medicine, San Francisco, Calif.)

Gal, Fung, and Greenberg (1) showed that certain substituted malononitriles partially inhibited the growth of some transplantable tumors in mice. Clinical trial of two chemicals from their series was therefore undertaken.

Nine patients, as given in Table 1, were selected. All had advanced neoplastic disease, substantiated by relevant biopsy. Periodic clinical examinations, including measurement of accessible tumors, were performed. Weekly examinations were carried out on the blood and urine, as well as chemical determinations of the blood for albumin, globulin, nonprotein nitrogen and bilirubin.

p-Nitrobenzalmalononitrile was dispersed as a 5 per cent suspension in sesame oil, and 5-nitrofururalmalononitrile was dispersed as a 10 per cent suspension in propylene glycol. The chemicals were injected intramuscularly, once a day in 7 patients and every other day in one patient; one patient received a single dose only. Thus, daily doses of p-nitrobenzalmalononitrile were up to 15 mg/kg body weight; and of 5-nitrofururalmalononitrile, up to 40 mg/kg body weight.

All patients complained of considerable pain at the site of injection, but no severe local reactions were observed. There were no acute effects upon pulse, respiration, temperature, blood pressure, or electrocardiographic patterns. No significant or consistent alterations in the blood cell counts, urine, or chemical constituents of the blood were detected.

Blood levels of thiocyanate were studied in five patients. Following a single injection of 0.7 gm. of p-nitrobenzalmalononitrile, the blood thiocyanate rose from 0.1 to 0.8 mg/100 cc within 24 hours in one patient; in the second patient, the blood thiocyanate level rose steadily from 0.6 to 3.6 mg/100 cc during a course of 5.35 gm. given in 13 days. No significant or consistent rises were seen in three patients who received 1.5, 1.8, and 2.0 gm. of 5-nitrofururalmalononitrile, respectively.

In none of the patients was there an observable effect upon the primary tumor or its metastases. No toxic effects were seen.

<table>
<thead>
<tr>
<th>CASE NO.</th>
<th>SEX</th>
<th>AGE</th>
<th>DIAGNOSIS</th>
<th>Dose/DAY (gm.)</th>
<th>DAYS USED</th>
<th>TOTAL DOSE (gm.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>39</td>
<td>Carcinoma, nasopharynx</td>
<td>0.7</td>
<td>1</td>
<td>0.7</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>62</td>
<td>Carcinoma, lung</td>
<td>0.03-0.15</td>
<td>18</td>
<td>1.61</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>10</td>
<td>Osteogenic sarcoma</td>
<td>0.1-0.9</td>
<td>13</td>
<td>5.35</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>47</td>
<td>Carcinoma, antrum</td>
<td>0.1</td>
<td>10</td>
<td>1.0</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>49</td>
<td>Carcinoma, nasopharynx</td>
<td>0.1-0.2</td>
<td>10</td>
<td>1.1</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>50</td>
<td>Carcinoma, nasopharynx</td>
<td>0.1-0.9</td>
<td>10</td>
<td>5.4</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>55</td>
<td>Carcinoma, testis</td>
<td>0.1-0.5</td>
<td>5</td>
<td>1.5</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>20</td>
<td>Osteogenic sarcoma</td>
<td>0.3-1.0</td>
<td>8</td>
<td>6.8</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>47</td>
<td>Carcinoma, lung</td>
<td>0.1-0.9</td>
<td>11</td>
<td>9.9</td>
</tr>
</tbody>
</table>

Table 1
Substituted Malononitriles in Patients with Cancer

It is concluded that p-nitrobenzal- and 5-nitrofururalmalononitrile, at the doses, length of courses, route, and vehicles employed had no effect upon the specific neoplasms observed in nine patients, and that no toxic effects were elicited.

REFERENCES
Substituted Malononitriles in Neoplastic Diseases in Man

N. L. Petrakis, H. R. Bierman and M. B. Shimkin


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/12/8/573.citation

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.